Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
6MP or Calcitriol vs. Purinethol · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Delayed Release 6MP or Calcitriol vs. Purinethol | DRUG | - |
Inclusion Criteria: * Male or Female patients, aged 18-75 years with moderate Crohn's Disease (CDAI score \>=220 and \<=400 at screening), with or without adjunctive mesalamine treatment, 12 with involvement of the ileum and three without ileal involvement * Definitive diagnosis of active inflammat...
Top 15 of 17 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 6 | PHASE3 | Duvakitug, SAR441566, balinatunfib, SAR442970 |
| AbbVie, Inc. | ABBV | 16 | PHASE3 | Risankizumab, Upadacitinib, Lutikizumab, Trosunilimab, ABBV-8736 |
| Eli Lilly and Company | LLY | 8 | PHASE3 | Mirikizumab, Tirzepatide, MORF-057, LY4395089 |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 16 | PHASE3 | Vedolizumab, Zasocitinib, Darvadstrocel |
| Johnson & Johnson | JNJ | 24 | PHASE3 | Ustekinumab, Guselkumab, JNJ-78934804, Golimumab, Icotrokinra |
| Merck & Co., Inc. | MRK | 2 | PHASE3 | Tulisokibart |
| AstraZeneca PLC | AZN | 2 | PHASE2 | AZD7798 |
| Spyre Therapeutics, Inc | SYRE | 2 | PHASE2 | SPY001, SPY002, SPY003 |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Abivax SA Sponsored ADR | ABVX | 1 | PHASE2 | Obefazimod |
| Shattuck Labs, Inc. | STTK | 1 | PHASE2 | SL-325 |
| AgomAb Therapeutics NV ADR | AGMB | 2 | PHASE2 | Ontunisertib |
| Hoffmann-La Roche | RHHBY | 1 | PHASE2 | Afimkibart |
| Pfizer Inc. | PFE | 1 | PHASE2 | Etrasimod |
| Palisade Bio, Inc. | PALI | 1 | PHASE1 | PALI-2108 |
6MP or Calcitriol vs. Purinethol refers to a small molecule therapy studied for Crohn's Disease. It is also known as Delayed Release 6MP or Calcitriol vs. Purinethol. The approach compares targeted, local delivery of drugs against Purinethol in a Phase 1 study conducted in Israel.
6MP or Calcitriol vs. Purinethol was studied for the treatment of Crohn's Disease, a gastrointestinal inflammatory condition. The Phase 1 trial evaluated targeted, local delivery of drugs to treat Crohn's Disease in adult patients aged 18 years and older.
6MP or Calcitriol vs. Purinethol is developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. The company sponsored the Phase 1 study of this small molecule therapy for Crohn's Disease.
6MP or Calcitriol vs. Purinethol is in Phase 1 development. The single Phase 1 trial has been completed, and no active trials are currently listed. It is an investigational therapy and has not been approved for Crohn's Disease.
6MP or Calcitriol vs. Purinethol was evaluated in one completed Phase 1 trial, NCT00287170, titled Efficacy Study of Targeted, Local Delivery of Drugs to Treat Crohn's Disease. The trial enrolled 15 adults in Israel, used a randomized design, and was uncontrolled.
Yes, 6MP or Calcitriol vs. Purinethol is also known as Delayed Release 6MP or Calcitriol vs. Purinethol. Both names refer to the same small molecule therapy developed by Teva Pharmaceutical Industries Limited for Crohn's Disease.